Gambro makes the strategic decision to focus on its core businesses and sell its global PD business to Fresenius Medical Care

“This transaction allows us to prioritize our investments in the areas where we believe we have the biggest opportunities to create the most value, for our customers and our company. Focusing on our core HD business including the home segment, is a strategic priority for us and an integral part of our growth strategy.” says Francisco Canal, President Gambro Chronic Business Unit. “We are committed to invest in innovations that will allow physicians to individualize patient-care for an optimal dialysis therapy delivery.”

Gambro believes FME will be a value adding owner of Gambro’s PD business, which further supports Gambro’s decision to prioritize its investments in the hemodialysis (HD) market.

“We see strong potential both in our Chronic HD business as well as within our Acute segment where we today are the market leader. This is an exciting time as we continue to focus and build an even stronger Company for the future.” says Thomas Glanzmann, Gambro President and CEO. “I would also like to take this opportunity to thank our dedicated employees who have built a strong PD business over the years. With Fresenius Medical Care as the new owner, they will have the opportunity to continue to develop this business.” 

The transaction is subject to necessary regulatory and other approvals as well as relevant work council consultations. Both companies expect the acquisition to close before the end of the year.

For further information please contact:
Maria Lundbäck, Director External Communications Gambro, tel. +46 705 13 6534